04/2015
Discovery of tumor types highly susceptible to FASN inhibition and biomarker candidates for clinical analysis
AACR Annual Meeting
Read More
04/2015
Biomarker and PK/PD analyses of first-in-class FASN inhibitor TVB-2640 in a first-in-human phase 1 study in solid tumor patients
AACR Annual Meeting
Read More
04/2015
Report of a First-In-Human Study of the First-In-Class Fatty Acid Synthase (FASN) Inhibitor, TVB-2640
AACR Annual Meeting
Read More
11/2014
Initial report of a first-in-human study of the first-in-class fatty acid synthase (FASN) inhibitor, TVB-2640
EORTC-NCI-AACR International Conference
Read More
11/2014
Mechanistic analysis of reversible FASN inhibition in preclinical tumor models identifies highly susceptible tumor types and enriches biomarker discovery for clinical applications
EORTC-NCI-AACR International Conference
Read More
04/2014
Efficacy of FASN-selective small molecule inhibitors of preclinical tumor models
AACR Annual Meeting
Read More
10/2013
Characterization of small-molecule FASN inhibitors in preclinical tumor models
AACR-NCI-EORTC International Conference
Read More